July 31 Company Quick Takes: Bayer, Orion win approval in prostate cancer; plus Keytruda, Roche-Spark, UC v. Broad and more

Bayer, Orion androgen receptor inhibitor approved for prostate cancer
FDA approved an NDA for Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp. (HSE:ORNAV; HSE:ORNBV) to treat non-metastatic castration-resistant prostate cancer. The oral androgen receptor inhibitor, which was under Priority Review, prevents androgen receptor-mediated transcription by inhibiting translocation of the androgen receptor to the nucleus -- potentially providing

Read the full 571 word article

User Sign In